NCT07057349View on ClinicalTrials.gov

CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

February 28, 2029

Conditions
Metastatic CancerUnresectable Solid Tumor
Interventions
DRUG

[18F]CSB-321

\[18F\]CSB-321 is a PET imaging agent that is bound to released granzyme B from T-cells

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Cytosite Biopharma Inc.

INDUSTRY

NCT07057349 - CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer | Biotech Hunter | Biotech Hunter